<DOC>
	<DOCNO>NCT02914470</DOCNO>
	<brief_summary>This single centre , 3+3 , dose finding , open label , phase 1b clinical study carboplatin cyclophosphamide , combination atezolizumab .</brief_summary>
	<brief_title>Carboplatin-cyclophosphamide Combined With Atezolizumab</brief_title>
	<detailed_description>The start dose carboplatin AUC 5mg/ml*min , cyclophosphamide 600mg/m2 atezolizumab 840 mg , administer intravenously . One cycle 28 day . On day 1 carboplatin , cyclophosphamide atezolizumab administer . On day 15 atezolizumab administer . Patients treated loss clinical benefit , unacceptable toxicity , withdrawal consent . It expect 6-12 patient enrol , depend safety issue observe .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histological cytological proof advance breast cancer ( M1 ) advance gynaecological cancer ( cervix ( M1 , FIGO IVA/IVB ) , ovarian ( recurrence carboplatin and/or paclitaxel ) stage 4 cervical endometrial ( T3T4 , FIGO IVA/IVB ) cancer ) pretreated maximally one line systemic chemotherapy advance set line hormonal therapy advance disease potentially benefit carboplatincyclophosphamide atezolizumab . ( prior ( neo ) adjuvant chemotherapy accept count one line , since administer early stage disease ) ; Men woman &gt; = 18 year ; Able willing give write informed consent ; WHO performance status 0 1 ; Life expectancy &gt; = 3 month , allow adequate follow toxicity evaluation antitumor activity ; Minimal acceptable safety laboratory value Any treatment investigational drug within 28 day prior receive first dose investigational treatment ; 21 day standard ( neo ) adjuvant chemotherapy , hormonal immunotherapy ; Known clinically significant liver disease , include active viral , alcoholic , hepatitis , cirrhosis , fatty liver , inherit liver disease ; Known hypersensitivity Chinese hamster ovary cell product recombinant human antibody . Women positive pregnancy test ( urine serum ) and/or ware breast feeding ; Unreliable contraceptive method . Women men enrol trial must agree use reliable contraceptive method throughout study ( adequate contraceptive method : oral , injected implant hormonal method , intrauterine device system , condom barrier contraceptive measure , sterilization true abstinence ) ; Uncontrolled infectious disease know Human Immunodeficiency Virus HIV1 HIV2 type patient ; Positive test HIV Active hepatitis B ( define positive hepatitis B surface antigen [ HbsAg ] test screening ) active hepatitis C Patients past hepatitis B virus ( HBV ) infection resolve HBV infection ( define negative HBsAg test positive antibody hepatitis B core antigen [ antiHBc ] antibody test ) eligible . Patients positive hepatitis C virus ( HCV ) antibody eligible polymerase chain reaction ( PCR ) negative HCV RN Active tuberculosis Receipt live , attenuate vaccine within 28 day prior enrolment anticipation live , attenuated vaccine require study Prior treatment CD137 agonists immune checkpoint blockade therapy , include antiCTLA4 ( like Ipilimumab ) , antiPD1 ( like pemprolizumab ) , antiPDL1 therapeutic antibody ( like atezolizumab ) . Treatment systemic immunostimulatory agent ( include limit interferon IL2 ) within 28 day five halflives drug ( whichever short ) prior enrolment ; Treatment systemic corticosteroid systemic immunosuppressive medication ( include limit prednisone , dexamethasone , cyclophosphamide , azathioprine , methotrexate , thalidomide , antitumor necrosis factor [ TNF ] agent ) within 28 day prior enrolment , anticipated requirement systemic immunosuppressive medication trial Patients receive acute , lowdose , systemic immunosuppressant medication ( e.g. , onetime dose dexamethasone nausea ) may enrol study . The use inhale corticosteroid chronic obstructive pulmonary disease , mineralocorticoid ( e.g. , fludrocortisone ) patient orthostatic hypotension , lowdose supplemental corticosteroid adrenocortical insufficiency allow ; Patients know alcoholism , drug addiction and/or psychiatric physiological condition opinion investigator would impair study compliance ; Recent myocardial infarction ( &lt; six month prior enrolment ) unstable angina ; New York Heart Association Class II great congestive heart failure . If cardiac failure suspect : LVEF MUGA ultrasound must â‰¥ 50 % perform within 28 day prior enrolment . Symptomatic brain metastasis . If adequately treat resection and/or irradiation patient least four week completely free symptom metastasis without medication relate metastasis patient could eligible inand exclusion criterion obey . Known leptomeningeal metastasis ; History autoimmune disease include , limited , systemic lupus erythematosus , rheumatoid arthritis , imflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , Sjogren 's syndrome , Bell 's palsy , GuillainBarre syndrome , multiple sclerosis , vasculitis glomerulonephritis ; Patients history autoimmunerelated hypothyroidism stable dose thyroid replacement hormone may eligible study ; Prior allogenic stem cell solid organ transplantation ; History idiopathic pulmonary fibrosis ( include bronchiolitis obliterans organize pneumonia ) evidence active pneumonitis screen chest compute tomography scan . History radiation pneumonitis radiation field ( fibrosis ) permit . Severe infection within 28 day prior enrolment , include , limited , hospitalization complication infection , bacteraemia , severe pneumonia ; Signs symptom significant infection within 2 week prior enrolment ; Received oral IV antibiotic within 2 week prior enrolment Patients receive prophylactic antibiotic ( e.g. , prevention urinary tract infection chronic obstructive pulmonary disease ) eligible ; History stroke transient ischemic attack ( TIA ) within 6 month prior enrolment ; Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior enrolment anticipation need major surgical procedure course study Any medical condition yet specify consider possibly , probably definitely interfere study procedure , include adequate followup compliance and/or would jeopardize safe treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>advanced</keyword>
</DOC>